IP Library › Granted Patent US 7,485,295
Granted Patent B2
US 7,485,295 · App. 11/527,318 · Granted Feb 3, 2009

Compositions and methods of using chondroitinase ABCI mutants

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,485,295
App. No.
11/527,318
Granted
Feb 3, 2009
Kind
B2
Abstract

One aspect of the present invention relates to mutants of chondroitinase ABCI. Such chondroitinase ABCI mutants exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including exposure to UV light or heat. Methods of using chondroitinase ABCI mutant enzymes are also provided.

Claims (13)

1. A mutant chondroitinase ABCI enzyme, wherein said enzyme comprises BE7 (SEQ ID NO:2).

2. A method of treating a central nervous system injury comprising administering a therapeutically effective amount of a mutant chondroitinase ABCI enzyme comprising BE7 (SEQ ID NO:2).

3. The method of claim 2 , wherein the mutant chondroitinase ABCI enzyme is administered following a contusion injury to the central nervous system.

4. The method of claim 2 , wherein the mutant chondroitinase ABCI enzyme is administered following a non-contusion injury to the central nervous system.

5. The method of claim 2 , wherein the mutant chondroitinase ABCI enzyme is administered following a spinal cord injury.

6. The method of claim 2 , wherein the mutant chondroitinase ABCI enzyme is administered locally.

7. The method of claim 6 , wherein the local administration is selected from intrathecal and topical administration.

8. A method of promoting neuronal outgrowth comprising administering a therapeutically effective amount of a mutant chondroitinase ABCI enzyme comprising BE7 (SEQ ID NO:2).

9. The method of claim 8 , wherein the mutant chondroitinase ABCI enzyme is administered following a contusion injury to the central nervous system.

10. The method of claim 8 , wherein the mutant chondroitinase ABCI enzyme is administered following a non-contusion injury to the central nervous system.

11. The method of claim 8 , wherein the mutant chondroitinase ABCI enzyme is administered following a spinal cord injury.

12. The method of claim 8 , wherein the mutant chondroitinase ABCI enzyme is administered locally.

13. The method of claim 12 , wherein the local administration is selected from intrathecal and topical administration.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded May 31, 2017
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: NEURONEX, INC.; CIVITAS THERAPEUTICS, INC.; ACORDA THERAPEUTICS, INC.
Reel/Frame 042643/0878 →
SECURITY INTEREST Recorded Jun 10, 2016
From: ACORDA THERAPEUTICS, INC.; CIVITAS THERAPEUTICS, INC.; NEURONEX, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 038950/0436 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2007
From: CAGGIANO, ANTHONY O.; IACI, JENNIFER; VECCHIONE, ANDREA; MARKENSOHN, ELIZABETH
To: ACORDA THERAPEUTICS, INC.
Reel/Frame 018766/0887 →